Home » TARO RECEIVES APPROVAL TO MARKET GENERIC LOPROX
TARO RECEIVES APPROVAL TO MARKET GENERIC LOPROX
The FDA has approved Taro Pharmaceutical Industries' abbreviated new drug application for Ciclopirox Topical Suspension USP, 0.77 percent.
Taro's product is the generic equivalent of Medicis Pharmaceutical's Loprox, which is intended to treat fungal infections of the skin. Ciclopirox topical suspension products had annual U.S. sales of approximately $34.2 million in 2004, Taro said.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May